Skip to main content

Welkom bij Erasmus MC & Bohn Stafleu van Loghum

Erasmus MC heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Registreer

Om ook buiten de locaties van Erasmus MC, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van Erasmus MC.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top
Gepubliceerd in:

01-02-2011 | BLADDER CANCER IN THE NETHERLANDS

Variations in treatment policies and outcome for bladder cancer in the Netherlands

Auteurs: drs. C.A. Goossens-Laan, dr. O. Visser, drs. M.W.J.M. Wouters, dr. M.L.E.A. Jansen-Landheer, prof. dr. J.W. Coebergh, prof. dr. C.J.H. van de Velde, dr. M.C.C.M. Hulshof, dr. P.J.M. Kil

Gepubliceerd in: Tijdschrift voor Urologie | Uitgave 1/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Summary

Aim: To describe the population-based variation in treatment policies and outcome for bladder cancer in the Netherlands.
Methods: All newly diagnosed patients with primary bladder cancers during 2001-2006 were selected from the Netherlands Cancer Registry (n = 29,206). Type of primary treatment was analysed according to Comprehensive Cancer Centre region, hospital type (academic, non-academic teaching or other hospitals) and volume (≤5, 6-10 or >10 cystectomies yearly). For stage II-III patients undergoing cystectomy we analysed the proportion of lymph node dissections and 30-days mortality.
Results: 44% of patients with stage II-III bladder cancer underwent cystectomy, while 26% were not treated with curative intent. Cystectomy was the preferred option in three of nine regions, radiotherapy in two, and two regions waived curative treatment more often. Between 2001 and 2006 the number of cystectomies increased with 20% (n = 108). 21% (n = 663) of these procedures were performed in 44 low volume hospitals. In 79% of the cystectomies lymph node dissections were performed, more often in high and medium-volume centers (82% and 81% respectively) than in low-volume hospitals (71%, the odds ratio being 1.5). The overall 30-days postoperative mortality rate was 3.4% and increased with older age. It was significantly lower in high-volume centers (1.2%).
Conclusion: Treatment policies for muscle-invasive bladder cancer in the Netherlands showed regional preferences and a gradual increase of cystectomy. Cystectomy albeit considered as golden standard, was performed in a minority of the muscleinvasive cases. In high-volume institutions, lymph node dissection rates were higher and post-operative mortality rates were lower.
Literatuur
2.
go back to reference Ferlay J, Randi G, Bosetti C, Levi F, Negri E, Boyle P, La VC. Declining Mortality From Bladder Cancer in Europe. BJU Int. 2008;101(1):11–9.PubMed Ferlay J, Randi G, Bosetti C, Levi F, Negri E, Boyle P, La VC. Declining Mortality From Bladder Cancer in Europe. BJU Int. 2008;101(1):11–9.PubMed
3.
go back to reference Karim-Kos HE, de VE, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent Trends of Cancer in Europe: a Combined Approach of Incidence, Survival and Mortality for 17 Cancer Sites Since the 1990s. Eur J Cancer. 2008;44(10):1345–89.PubMedCrossRef Karim-Kos HE, de VE, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent Trends of Cancer in Europe: a Combined Approach of Incidence, Survival and Mortality for 17 Cancer Sites Since the 1990s. Eur J Cancer. 2008;44(10):1345–89.PubMedCrossRef
4.
go back to reference Batterman JJ, Feller N, Hamelers-Paulus HWG, Reijke TM de, Witjes JA. Guideline Diagnostics, treatment and follow-up of the Urothelial Cell Carcinoma of the bladder. 2008, Dutch Projectgroep Guideline Bladder Cancer; the Netherlands Cancer Registry. Batterman JJ, Feller N, Hamelers-Paulus HWG, Reijke TM de, Witjes JA. Guideline Diagnostics, treatment and follow-up of the Urothelial Cell Carcinoma of the bladder. 2008, Dutch Projectgroep Guideline Bladder Cancer; the Netherlands Cancer Registry.
5.
go back to reference Hollenbeck BK, Wei Y, Birkmeyer JD. Volume, Process of Care, and Operative Mortality for Cystectomy for Bladder Cancer. Urology. 2007;69(5):871–5.PubMedCrossRef Hollenbeck BK, Wei Y, Birkmeyer JD. Volume, Process of Care, and Operative Mortality for Cystectomy for Bladder Cancer. Urology. 2007;69(5):871–5.PubMedCrossRef
6.
go back to reference Wouters M, Krijen P, Le Cessie S, Gooiker G, Guicherit O, Marinelli A, Kievit J, Tollenaar R. Volume- or Outcome-Based Referral to Improve Quality of Care for Esophageal Cancer Surgery in the Netherlands. J Surg Oncol. 2009;99(8):481–7.PubMedCrossRef Wouters M, Krijen P, Le Cessie S, Gooiker G, Guicherit O, Marinelli A, Kievit J, Tollenaar R. Volume- or Outcome-Based Referral to Improve Quality of Care for Esophageal Cancer Surgery in the Netherlands. J Surg Oncol. 2009;99(8):481–7.PubMedCrossRef
7.
go back to reference van Heek NT, Kuhlmann KF, Scholten RJ, Castro SM de, Busch OR, Gulik TM van, Obertop H, Gouma DJ. Hospital Volume and Mortality After Pancreatic Resection: a Systematic Review and an Evaluation of Intervention in the Netherlands. Ann Surg. 2005;242(6):781–8, discussion. van Heek NT, Kuhlmann KF, Scholten RJ, Castro SM de, Busch OR, Gulik TM van, Obertop H, Gouma DJ. Hospital Volume and Mortality After Pancreatic Resection: a Systematic Review and an Evaluation of Intervention in the Netherlands. Ann Surg. 2005;242(6):781–8, discussion.
8.
go back to reference Fritz A. International Classification of Diseases for Oncology. Geneva: World Health Organization; 2000. Fritz A. International Classification of Diseases for Oncology. Geneva: World Health Organization; 2000.
9.
go back to reference Schouten LJ, Jager JJ, Brandt PA van den. Quality of Cancer Registry Data: a Comparison of Data Provided by Clinicians With Those of Registration Personnel. Br J Cancer. 1993;68(5):974–7.PubMedCrossRef Schouten LJ, Jager JJ, Brandt PA van den. Quality of Cancer Registry Data: a Comparison of Data Provided by Clinicians With Those of Registration Personnel. Br J Cancer. 1993;68(5):974–7.PubMedCrossRef
10.
go back to reference Schouten LJ, Hoppener P, Brandt PA van den, Knottnerus JA, Jager JJ. Completeness of Cancer Registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22(3):369–76.PubMedCrossRef Schouten LJ, Hoppener P, Brandt PA van den, Knottnerus JA, Jager JJ. Completeness of Cancer Registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22(3):369–76.PubMedCrossRef
11.
go back to reference Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.
12.
go back to reference Witjes JA. Management of the First Recurrence of T1G3 Bladder Cancer: Does Intravesical Chemotherapy Deserve a Chance? Urol Oncol. 2009;27(3):322–4.PubMedCrossRef Witjes JA. Management of the First Recurrence of T1G3 Bladder Cancer: Does Intravesical Chemotherapy Deserve a Chance? Urol Oncol. 2009;27(3):322–4.PubMedCrossRef
13.
go back to reference Hall MC, Chang S, Dalbagni G, Pruthi RS, Schellhammer PF, Seigne JD, Skinner EC, Wolf JS, Bell HS, Florer PM, Glickham D, Pope S, Hubbard H, Budd E, Folmer M, Moore K, Kebe K. Management of Nonmuscle Invasive Bladder Cancer: (Stages Ta,T1, and Tis): Revised (2007). 10–1-2007. American Urological Association Education and Research, Inc. Hall MC, Chang S, Dalbagni G, Pruthi RS, Schellhammer PF, Seigne JD, Skinner EC, Wolf JS, Bell HS, Florer PM, Glickham D, Pope S, Hubbard H, Budd E, Folmer M, Moore K, Kebe K. Management of Nonmuscle Invasive Bladder Cancer: (Stages Ta,T1, and Tis): Revised (2007). 10–1-2007. American Urological Association Education and Research, Inc.
14.
go back to reference Jakse G, Algaba F, Fossa S, Stenzyl A, Sternberg C. Guidelines on bladder cancer, muscle-invasive and metastatic. European association of Urology; 2006. Jakse G, Algaba F, Fossa S, Stenzyl A, Sternberg C. Guidelines on bladder cancer, muscle-invasive and metastatic. European association of Urology; 2006.
14.
go back to reference Jahnson S, Damm O, Hellsten S, Holmang S, Liedberg F, Ljungberg B, Malmstrom PU, Mansson W, Stromberg F, Wijkstom H. A Population-Based Study of Patterns of Care for Muscle-Invasive Bladder Cancer in Sweden. Scand J Urol Nephrol. 2009;43(4):271–6.PubMedCrossRef Jahnson S, Damm O, Hellsten S, Holmang S, Liedberg F, Ljungberg B, Malmstrom PU, Mansson W, Stromberg F, Wijkstom H. A Population-Based Study of Patterns of Care for Muscle-Invasive Bladder Cancer in Sweden. Scand J Urol Nephrol. 2009;43(4):271–6.PubMedCrossRef
16.
go back to reference Hollenbeck BK, Dunn RL, Miller DC, Daignault S, Taub DA, Wei JT. Volume-Based Referral for Cancer Surgery: Informing the Debate. J Clin Oncol. 2007;25(1):91–6.PubMedCrossRef Hollenbeck BK, Dunn RL, Miller DC, Daignault S, Taub DA, Wei JT. Volume-Based Referral for Cancer Surgery: Informing the Debate. J Clin Oncol. 2007;25(1):91–6.PubMedCrossRef
17.
go back to reference McCabe JE, Jibawi A, Javle P. Defining the Minimum Hospital Case- Load to Achieve Optimum Outcomes in Radical Cystectomy. BJU Int. 2005;96(6):806–10.PubMedCrossRef McCabe JE, Jibawi A, Javle P. Defining the Minimum Hospital Case- Load to Achieve Optimum Outcomes in Radical Cystectomy. BJU Int. 2005;96(6):806–10.PubMedCrossRef
18.
go back to reference de Vries RR, Visser O, Nieuwenhuijzen JA, Horenblas S. Outcome of Treatment of Bladder Cancer: a Comparison Between Low-Volume Hospitals and an Oncology Centre. World J Urol. 2010. de Vries RR, Visser O, Nieuwenhuijzen JA, Horenblas S. Outcome of Treatment of Bladder Cancer: a Comparison Between Low-Volume Hospitals and an Oncology Centre. World J Urol. 2010.
19.
go back to reference Chang SS, Alberts G, Cookson MS, Smith JA, Jr. Radical Cystectomy Is Safe in Elderly Patients at High Risk. J Urol. 2001;166(3):938–41.PubMedCrossRef Chang SS, Alberts G, Cookson MS, Smith JA, Jr. Radical Cystectomy Is Safe in Elderly Patients at High Risk. J Urol. 2001;166(3):938–41.PubMedCrossRef
20.
go back to reference Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical Cystectomy in the Elderly: Comparison of Clincal Outcomes Between Younger and Older Patients. Cancer. 2005;104(1):36–43.PubMedCrossRef Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical Cystectomy in the Elderly: Comparison of Clincal Outcomes Between Younger and Older Patients. Cancer. 2005;104(1):36–43.PubMedCrossRef
21.
go back to reference Lund L, Jacobsen J, Clark P, Borre M, Norgaard M. Impact of Comorbidity on Survival of Invasive Bladder Cancer Patients, 1996–2007: A Danish Population-Based Cohort Study. Urology. 2010;75(2):393–8.PubMedCrossRef Lund L, Jacobsen J, Clark P, Borre M, Norgaard M. Impact of Comorbidity on Survival of Invasive Bladder Cancer Patients, 1996–2007: A Danish Population-Based Cohort Study. Urology. 2010;75(2):393–8.PubMedCrossRef
22.
go back to reference Froehner M, Brausi MA, Herr HW, Muto G, Studer UE. Complications Following Radical Cystectomy for Bladder Cancer in the Elderly. Eur Urol. 2009;56(3):443–54.PubMedCrossRef Froehner M, Brausi MA, Herr HW, Muto G, Studer UE. Complications Following Radical Cystectomy for Bladder Cancer in the Elderly. Eur Urol. 2009;56(3):443–54.PubMedCrossRef
23.
go back to reference Albertsen P. Regionalizing urologic cancer care: appropriate health care policy? Urol Oncol. 2010;28(1):1–3.PubMedCrossRef Albertsen P. Regionalizing urologic cancer care: appropriate health care policy? Urol Oncol. 2010;28(1):1–3.PubMedCrossRef
24.
go back to reference Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EB, Saldin K, Dinney CP. Correlation Between Annual Volume of Cystectomy, Professional Staffing, and Outcomes: a Statewide, Population-Based Study. Cancer. 2005;104(5):975–84.PubMedCrossRef Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, Avritscher EB, Saldin K, Dinney CP. Correlation Between Annual Volume of Cystectomy, Professional Staffing, and Outcomes: a Statewide, Population-Based Study. Cancer. 2005;104(5):975–84.PubMedCrossRef
25.
go back to reference Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A. Selective Referral to High-Volume Hospitals: Estimating Potentially Avoidable Deaths. JAMA. 2000;283(9):1159–66.PubMedCrossRef Dudley RA, Johansen KL, Brand R, Rennie DJ, Milstein A. Selective Referral to High-Volume Hospitals: Estimating Potentially Avoidable Deaths. JAMA. 2000;283(9):1159–66.PubMedCrossRef
25.
go back to reference Black PC, Brown GA, Dinney CP. Should Cystectomy Only Be Performed at High-Volume Hospitals by High-Volume Surgeons? Curr Opin Urol. 2006;16(5):344–9.PubMedCrossRef Black PC, Brown GA, Dinney CP. Should Cystectomy Only Be Performed at High-Volume Hospitals by High-Volume Surgeons? Curr Opin Urol. 2006;16(5):344–9.PubMedCrossRef
26.
go back to reference Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere WR, Sarosdy MF, Crawford ED. Surgical Factors Influence Bladder Cancer Outcomes: a Cooperative Group Report. J Clin Oncol. 2004;22(14):2781–9.PubMedCrossRef Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere WR, Sarosdy MF, Crawford ED. Surgical Factors Influence Bladder Cancer Outcomes: a Cooperative Group Report. J Clin Oncol. 2004;22(14):2781–9.PubMedCrossRef
27.
go back to reference Goossens-Laan C, Kil P, Oudshoorn F, Roukema A, Bosch R, Vries J de. Quality of Care Indicators for Muscle-Invasive Bladder Cancer. Urology. 74(4), S104–S105. Goossens-Laan C, Kil P, Oudshoorn F, Roukema A, Bosch R, Vries J de. Quality of Care Indicators for Muscle-Invasive Bladder Cancer. Urology. 74(4), S104–S105.
29.
go back to reference Nieuwenhuijzen JA, Vries RR de, Bex A, Poel HG van der, Meinhardt W, Antonini N, Horenblas S. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol. 2008 Apr;53(4):834–42, discussion 842–4. Nieuwenhuijzen JA, Vries RR de, Bex A, Poel HG van der, Meinhardt W, Antonini N, Horenblas S. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol. 2008 Apr;53(4):834–42, discussion 842–4.
30.
go back to reference de Vries RR, Visser O, Nieuwenhuijzen JA, Horenblas S; Members of the Urological Oncology Working Group of the Comprehensive Cancer Centre Amsterdam. Outcome of treatment of bladder cancer: a comparison between low-volume hospitals and an oncology centre. World J Urol. 2010 Aug;28(4):431–7. de Vries RR, Visser O, Nieuwenhuijzen JA, Horenblas S; Members of the Urological Oncology Working Group of the Comprehensive Cancer Centre Amsterdam. Outcome of treatment of bladder cancer: a comparison between low-volume hospitals and an oncology centre. World J Urol. 2010 Aug;28(4):431–7.
Metagegevens
Titel
Variations in treatment policies and outcome for bladder cancer in the Netherlands
Auteurs
drs. C.A. Goossens-Laan
dr. O. Visser
drs. M.W.J.M. Wouters
dr. M.L.E.A. Jansen-Landheer
prof. dr. J.W. Coebergh
prof. dr. C.J.H. van de Velde
dr. M.C.C.M. Hulshof
dr. P.J.M. Kil
Publicatiedatum
01-02-2011
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Urologie / Uitgave 1/2011
Print ISSN: 2211-3037
Elektronisch ISSN: 2211-4718
DOI
https://doi.org/10.1007/s13629-011-0005-x